Mental-health patient groups have become increasingly dissatisfied with the pharmaceutical industry, according to our latest analysis of Corporate Reputation 2019.

In 2019, as few as 26% of 2019’s 75 respondent mental-health patient groups judged the industry to have an “Excellent” or “Good” corporate reputation that year, ranking the industry 5th out of 9 healthcare sectors. The equivalent 2019 figure from the 1,850 respondent patient groups of all therapy areas was 46%, ranking pharma 1st out of the nine healthcare sectors. Mental-health patient groups have traditionally been more sceptical of pharma than their peers of other therapy areas.